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Abstract
Background: Rett Syndrome (RTT), caused by a loss-of-function in the epigenetic modulator: X-linked methyl-CpG
binding protein 2 (MeCP2), is a pervasive neurological disorder characterized by compromised brain functions,
anxiety, severe mental retardation, language and learning disabilities, repetitive stereotyped hand movements and
developmental regression. An imbalance in the sympathetic and the parasympathetic nervous system
(dysautonomia) and the resulting autonomic storms is a frequent occurrence in patients with RTT. The prototypical
beta blocker propranolol has been used to manage sympathetic hyperactivity in patients with RTT.
Case presentation: A 13 year old girl with RTT was referred to the Centre for Interventional Paediatric
Psychopharmacology and Rare Diseases (CIPPRD), South London and Maudsley NHS Foundation Trust. Her clinical
picture included disordered breathing with concomitant hyperventilation and apnoea, epilepsy, scoliosis, no QT
prolongation (QT/QTc [372/467 ms on automated electrocardiogram [ECG], but manually calculated to be 440 ms]),
no cardiac abnormalities (PR interval: 104 ms, QRS duration: 78 ms), and generalised anxiety disorder (ICD-10-CM
Diagnosis Code F41.1). She was also constipated and was fed via percutaneous endoscopic gastrostomy (PEG). To
manage the dysautonomia, propranolol was given (5 mg and 10 mg) and in parallel her physiological parameters,
including heart rate, skin temperature and skin transpiration, were monitored continuously for 24 h as she went about
her activities of daily living. Whilst her skin temperature increased and skin transpiration decreased, unexpectedly there
was a significant paradoxical increase in the patient’s average heart rate following propranolol treatment.
Conclusion: Here, we present a unique case of a paradoxical increase in heart rate response following propranolol
treatment for managing dysautonomia in a child with RTT. Further studies are warranted to better understand the
underlying dysautonomia in patients with RTT and the impact this might have on treatment strategies in rare disorders
such as RTT.
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Background
Ever since Dr Andreas Rett first observed the marked hand
stereotypies (hand wringing) of two severely disabled
young girls in a paediatric clinic waiting room in Vienna
circa 1965, research into Rett Syndrome (RTT) has pro-
gressed at a significant rate. RTT is a neurodevelopmental
disorder that manifests in young girls with an incidence of
about 1: 10,000 female live births [1]. Although initial re-
ports suggested exclusivity of RTT in females, due to the
fact that in males the mutation was often embryonic lethal,
males with milder mutations can survive and at present 57
cases of RTT have been reported in males [2]. The clinical
picture presents with a constellation of neurological symp-
toms ranging from anxiety, replacement of meaningful
hand movements with repetitive stereotypies, seizures,
neurogenic apnoea, breathing abnormalities and a promin-
ent delay or absence in speech [3] but also less prominent
non-neurological pathologies such as osteopenia, scoliosis,
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gastrointestinal disorders, and a general retardation in
growth [3]. RTT belongs to a larger group of neurodeve-
lopmental disorders known as “synaptopathies” which are
usually disorders with aberrations in synaptic function
and/or morphology being implicated in the pathogenesis
of the disease. At a cellular level, evidence has indicated
that neurons in patients with RTT are smaller; more
densely packed, reduced in length and complexity, and re-
duced in the number of dendritic spines [4]. This specific
neuronal architecture might help to unravel the clinical
picture of the disease and provide mechanistic insight into
brainstem autonomic dysfunction in RTT. RTT has func-
tional convergence with other neurodevelopmental disor-
ders and is thought to share many of the altered molecular
signalling pathways with Autism Spectrum Disorder
(ASD). This partnership is underscored due to the fact that
individuals with RTT were often diagnosed as having ASD.
Indeed, about half of children with RTT also exhibit symp-
toms consistent with those of ASD [5].
Around 90% of cases of patients who exhibit classical
RTT have loss-of-function mutations of the critical epi-
genetic modulator: X-linked methyl-CpG binding protein
2 (MeCP2) [6] that is purported to cause neurological dys-
function by specifically disrupting long gene expression
within the brain [7]. Due to the chimeric expression of the
mutant allele and the pattern of X-linked inactivation,
RTT exhibits considerable pleiotropic heterogeneity and
the clinical picture ranges from individuals who are high
functioning, to those who are severely incapacitated. Indi-
viduals with RTT appear to develop normally up to 6–18
months of age. However, this is followed by a period of de-
velopmental stagnation and regression with significant
loss of speech and social interaction. It was unclear why
these symptoms manifest after this period of relative qui-
escence; however this quandary was deciphered recently
when Chen and colleagues showed that MeCP2 adopts
differing roles when recognising methylated DNA to regu-
late gene transcription in the mammalian CNS and this
contributes to the delayed onset of RTT pathologies [8].
Several key cellular players have been implicated in propa-
gating RTT pathology [9]; however the confounding re-
sults in the roles for some of the emerging players [10, 11]
casts doubt on whether they may actually play a substan-
tive role in the progression of RTT pathology. Research
investigating the pathologies of RTT is still in its infancy
and the clinical picture seems to be changing frequently.
Recent evidence has shown that deep brain stimulation
can improve the hippocampal memory deficits in a mouse
model of RTT [12] whilst SUMOylation of MeCP2 was
able to restore behavioural deficits in a mouse model of
RTT [13]. How well these findings extrapolate to studies
done in patients with RTT at present remains unclear.
Individuals with RTT might survive into adulthood;
however their life expectancy is curtailed due to the
higher frequency of sudden and unexpected death. Ana-
lysis of deaths from a British survey has shown that
about 25% of all deaths in RTT are sudden and unex-
pected [14] and it has been surmised that the torsado-
genic features in cardiac physiology that are intrinsic to
certain individuals with RTT could explain some of these
deaths [15]. Indeed, it has been shown that girls with
RTT have clinically significant prolongations in the QTc
interval and T-wave abnormalities in comparison to age-
matched healthy controls [16].
In terms of syndrome progression and the development
of dysautonomia, there is a scarcity within the evidence
base providing syndrome progression from a dysautono-
mia perspective in patients with RTT. It is likely that post-
translational modifications of long genes implicated in
neuronal development [7, 17] regulate the functional and
developmental versatility of MeCP2 in individuals with
RTT. Recent evidence has shown that MeCP2R306C muta-
tion prevents it from interacting with the NCoR/histone
deacetylase 3 (HDAC3) complex, which causes impair-
ments in social and cognitive functioning [18]. In the de-
veloping brain stem, this impairment will more than likely
have downstream effects such as perturbations in excita-
tory [19] and inhibitory [20] pathways, which in turn will
have knock-on effects on vital brain regions implicated in
sympathetic and parasympathetic elements of the auto-
nomic nervous system (ANS). Any imbalance will result
in dysautonomia; however whilst, autonomic manifesta-
tions in RTT include anxiety, pupillary dilation [21], raised
serotonin receptor binding in brain stem nuclei [22], low
vagal tone with poor vagal response to hyperventilation
[23], lower heart rate variability with prolonged QTcF [15]
and uncontrolled albeit normal sympathetic tone due to
minimal negative feedback of the parasympathetic system
[24], due to the inherent heterogeneous plasticity of RTT
particularly in terms of maturity-related brainstem func-
tioning [25], these manifestations are more than likely to
differ between individuals and so the precise trajectory in
terms of the developmental progression of dysautonomia
in RTT is at the moment unclear.
Given that dysautonomia is a cardinal feature of RTT,
a logical treatment regimen would be for the introduc-
tion of a cardio-protective agent to dampen down the
paroxysmal sympathetic hyperactivity that is frequently
encountered in individuals with RTT. The prototypical
beta-blocker propranolol is useful in this regard, as beta-
adrenergic receptor blockade might also help to amelior-
ate the somatic manifestations of dysautonomia such as
palpitations, tremor, diaphoresis and panic attacks which
occur in up to 75% of cases in RTT [26]. Despite these
findings, there is some circumspect for the role of beta
blockers as an efficacious agent for managing dysautono-
mia in individuals with RTT. Findings from murine stud-
ies have indicated that acute treatment with propranolol
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does not prevent ventricular tachycardia in mice lack-
ing MeCP2 that have an increased susceptibility to
ventricular arrhythmias [27]. Moreover, chronic pro-
pranolol has no effect on the prolongation of the
QTc interval and also failed to prevent cardiac ar-
rhythmias in MeCP2 deficient mice [28].
Given the finding that acute or chronic treatment with
propranolol might not be an effective therapy for man-
aging dysautonomia in RTT and about 20% of sudden
deaths in RTT being of cardiac origin, it is imperative to
explore these findings in humans. No prior case reports
have incorporated a psychiatric evaluation on the effect-
iveness of propranolol in managing dysautonomia in a
child with RTT. Hitherto in this current report, we spe-
cifically used the prototypical beta-blocker propranolol
to modify the dysautonomia in this patient with a view
to ameliorate the concomitant features such as cardiac
instability, diaphoresis and panic attacks.
Case presentation
In November 2013, a 13 year-old girl of British origin,
with a confirmed genetic and clinical diagnosis of Rett
Syndrome (RTT) was referred to the Centre for Inter-
ventional Paediatric Psychopharmacology and Rare Dis-
eases (CIPPRD), South London and Maudsley NHS
Foundation Trust. She presented with disordered breath-
ing with concomitant hyperventilation and apnoeas, epi-
lepsy, scoliosis (has had previous spinal cord surgery),
no QT prolongation (QT/QTc [372/467 ms on auto-
mated electrocardiogram [ECG], but manually calculated
to be 440 ms]), no cardiac abnormalities (PR interval:
104 ms, QRS duration: 78 ms), and generalised anxiety
disorder (ICD-10-CM Diagnosis Code F41.1). She was
also constipated and was fed via percutaneous endo-
scopic gastrostomy (PEG). Her treatment regimen in-
cluded lamotrigine (150 mg in the morning and 90 mg
in the evening), clobazam as required (10 mg rescue
medication for seizures), slow release melatonin (10 mg
in the evening), Movicol (2–3 sachets a day), omeprazole
(20 mg bid), L-carnitine supplements, calcium supple-
ments and Senokot (as required). She also received topical
treatment for a fungal skin infection.
Propranolol was newly administered (5 mg and 10 mg)
and physiological parameters including heart rate, skin
temperature and skin transpiration were monitored. This
was following a clinical protocol routinely used in the
CIPPRD, specifically the joint parent-clinician shared
decision-making model ‘Effective Dosing with Minimum
Side Effects’ (EDMS) strategy [29, 30]. The EDMS strat-
egy aims to use the lowest possible dose of a medication
to achieve adequate management of symptoms with
minimal side effects. Initially, 5 mg propranolol was ad-
ministered. At this dose, the patient did not experience
discomfort and so in a joint shared clinical decision
making process with the parents and clinicians, it was
decided that the dose of propranolol should be increased
to 10 mg. Following increase to 10 mg, the patient be-
came distressed and so treatment was terminated.
In order to estimate the baseline, these parameters
were also recorded in a treatment free period (24 h).
The CIPPRD is experienced in using a variety of wear-
able technologies for the non-invasive physiological
monitoring in patients and in this patient the Basis B1
wristband [31] was used for real-time monitoring that
recorded the heart rate, skin temperature and skin tran-
spiration continuously for 24 h as the teenager went
about her activities of daily life such as attending school
and when at home.
Data were manually obtained from the plots on the de-
vice webpage. The recorded physiological parameters were
divided into epochs of 30 min during the 24 h period for
each dose of medication. For each epoch, the average
value for all the physiological parameters was estimated
using a 5 min interval. Three one way ANOVAs (one for
each parameter) were performed. Unexpectedly there was
a concomitant significant concentration dependent in-
crease in heart rate from baseline (Fig. 1a) with the
maximum heart rate measured at 10 mg (F[1.806] = 17.010;
p < .001; baseline versus 5 mg dose: t[49] = −3.286; p < .016;
baseline versus 10 mg dose: t[49] = −6.649; p < .016, using
Bonferroni Correction for multiple comparisons [Bfc]).
The highest dose of propranolol (10 mg) paradoxically in-
creased the heart rate by about 10 beats per minute and
was associated with a significant worsening of night time
sleep quality and distress reported by the parent, and con-
sequently the treatment was discontinued. In parallel,
there was a significant increase in the skin temperature
(F[1.683] = 32.986; p < .001; baseline versus 10 mg dose:
t[49] = −8.084; p < .016 Bfc; 5 mg dose versus 10 mg dose:
t[49] = −6.941; p < .016 Bfc) (Fig. 1b) and a significant de-
crease in her skin transpiration (F[1.040] = 34.174; p < .001;
baseline versus 5 mg dose: t[49] = −5.653; p < .016 Bfc; base-
line versus 10 mg dose: t[49] = −6.664; p < .016 Bfc; 5 mg
dose versus 10 mg dose: t[49] = 2.875; p < .016 Bfc) (Fig. 1c).
In parallel, the Profile of Treatment Response (POTR)
scale was used to map the medication journey of the pa-
tient. The POTR is a clinician-completed scale, used
routinely in the CIPPRD as a clinical pharmacovigilance
tool. It allows for the assessment and monitoring of a
patient over time, and provides clinically meaningful in-
formation on the effectiveness of the medication (thera-
peutic Efficacy Index [EI]), change in symptoms, and
side-effects of the medication. The EI is assessed by the
degree of medication side effects and the improvement/
worsening of symptoms, which are denoted by a score
ranging from 0.25 to 4.00. In general, an EI score of >1.5
suggests that the medication is effective over time i.e., is
ameliorating the symptoms and improving the overall
Santosh et al. BMC Pediatrics  (2016) 16:194 Page 3 of 6
functioning of the patient without having unacceptable
side-effects. In this patient, the POTR revealed the
symptom profile of the patient in terms of anxiety, emo-
tional dysregulation, and sleep problems were made
much worse following 10 mg propranolol treatment.
Moreover, the EI values shifted from 1.00 at 5 mg pro-
pranolol to 0.33 following 10 mg propranolol treatment.
Collectively, these data indicate that propranolol treat-
ment had no therapeutic effect on the patient and sig-
nificantly interfered with functioning.
Conclusions
Here we described a 13 year old girl with RTT who after
being prescribed propranolol for 24 h at doses of 5 mg
and 10 mg demonstrated dose-dependent paradoxical
increases in heart rate. Such an unusual characteristic in a
cardiac phenotype following propranolol treatment for
managing dysautonomia has not been previously reported
in individuals with RTT. Baseline brainstem functions are
severely impacted in patients with RTT [23, 25, 32]. As a
consequence of this development brainstem immaturity,
brainstem autonomic functions can be severely affected.
Hitherto the resulting imbalance in the sympathetic and
the parasympathetic nervous system (dysautonomia) is a
prime suspect in causing cardiac instability and sudden
death which accounts for nearly 25% of all deaths in indi-
viduals with RTT [15]. In this regard, propranolol would
be considered an ideal cardio-protective agent to be used
in most patients; however our findings show that in pa-
tients with RTT this may not be the case. Evidence from
murine studies have indicated that acute treatment with
propranolol does not prevent ventricular tachycardia in
mice lacking MeCP2 that have an increased susceptibility
to ventricular arrhythmias [27]. Moreover, chronic pro-
pranolol has no effect on the prolongation of the QTc
interval and also failed to prevent cardiac arrhythmias in
MeCP2 deficient mice [28]. Coupled with the murine data,
collectively the results presented here strongly suggest
that caution should be stressed when using propranolol as
a treatment to manage dysautonomia in patients with
RTT or at the very least its use in RTT patients should be
carefully monitored.
Due to the divergent symptomatology in patients with
RTT, we cannot rule out the possibility that the paradox-
ical increase in heart rate following propranolol treatment
is caused by a mechanism other than dysautonomia, how-
ever, the fact that there were no clinically significant car-
diac abnormalities in the patients’ electrocardiogram
strongly suggests that these paradoxical increases in heart
rate were not due to an inherent cardiac abnormality
but rather likely to be governed by a sympathetic-
parasympathetic imbalance. As indicated previously [33],
one measure of ANS function is respiratory sinus
arrhythmia, which in turn is a metric of heart rate variabil-
ity associated with spontaneous breathing. In terms of
neurodevelopmental disorders, the patterns of autonomic
dysfunction are not so obvious. For example, respiratory
sinus arrhythmia of lower amplitude and faster heart rates
has been observed in children with ASD, and it is likely
that in these children the vagal brake is less effective and
thus the sympathetic influences cannot be sufficiently ab-
rogated [33, 34]). Other studies have explored autonomic
dysfunction in RTT [21–23, 25, 32], and have also used
heart variability as a marker for autonomic activity in pa-
tients with RTT [15]. Recently, an analysis of 132 females
with RTT aged between 2 and 43 years from a multi-
center study conducted from 1999 to 2012 in four
European countries has provided a basis for the dysauto-
nomia in patients with RTT [24]. In this study, all RTT
patients had dysautonomia and uncontrolled albeit
normal sympathetic tone due to minimal negative feed-
back of the parasympathetic system, which was the main
a b c
Fig. 1 Effect of propranolol on heart rate (a), skin temperature (b) and skin transpiration (c)
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contributing factor to the dysautonomia seen in these pa-
tients [24]. Further prospective studies will be able to shed
mechanistic insight into the basis for this dysautonomia
that is thought to be unique in patients with RTT [24].
This case report exemplifies this problem and general
practitioners and physicians should be cognisant of the
problems with the use of propranolol to manage dysautono-
mia in patients with RTT. As RTT exhibits pleiotropic het-
erogeneity, it has effects on multiple phenotypic traits that
manifest in a wide range of clinical symptoms. In view of
this, it is likely that the remodelling of cardiac physiology in
individuals with RTTand the resulting interplay between the
imbalance between the sympathetic and the parasympathetic
nervous system, in particular minimal negative feedback of
the parasympathetic branch as suggested recently [24], could
account for the paradoxical increase in heart rate observed.
A psychophysiological profiling of RTT patients using differ-
ent medication strategies will be a step forward when explor-
ing treatment options when managing rare disorders
such as RTT. This is a case report recording a para-
doxical effect on heart rate. A more detailed study
looking at larger numbers is warranted.
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